Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model

XU Hongjiang; SHI Wei; SONG Wei; ZHANG Ying; ZHAO Kaidi; ZHANG Yinsheng; YANG Ling; WANG Jinan

doi:10.11665/j.issn.1000-5048.20190413

Journal of China Pharmaceutical University > 2019 > 50(4): 475-480. > DOI: 10.11665/j.issn.1000-5048.20190413

XU Hongjiang, SHI Wei, SONG Wei, ZHANG Ying, ZHAO Kaidi, ZHANG Yinsheng, YANG Ling, WANG Jinan. Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model[J]. Journal of China Pharmaceutical University, 2019, 50(4): 475-480. DOI: 10.11665/j.issn.1000-5048.20190413

Citation:

PDF (2305 KB)

Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model

More Information

Graphical Abstract

Abstract

Abstract

This study aims to discuss the therapeutic effect of magnesium isoglycyrrhizinate on hepatitis B virus(HBV)transgenic mouse and its effect on cellular immunity and liver inflammation. The changes of serum aspartate aminotransferase(AST)and alanine aminotransferase(ALT)activity, the difference of serum hepatitis B surface antigen(HBsAg), liver tissue HBsAg mRNA, and the pathological morphological changes of liver tissue were detected to investigate the hepatic inflammatory lesions and the efficacy of magnesium isoglycyrrhizinate in HBV transgenic mouse. Peripheral blood lymphocytes were classified by flow cytometry, and serum cytokines were detected by cytometric bead array(CBA)to explore the mechanism of magnesium isoglycyrrhizinate to reduce hepatic inflammatory lesions in HBV transgenic mouse. After grouping HBV transgenic mouse with serum transaminase activity and 35 days of continuous administration, serum transaminases level in magnesium isoglycyrrhizinate ［15 mg/(kg ·d)］ group was significantly lower than that in control group(P< 0. 05), serum HBsAg protein and liver tissue HBsAg mRNA increased with time, but there was no significant difference between the two groups. The main pathological changes of liver were liver cell swelling, necrosis and focal inflammatory cell infiltration, and the pathological changes of liver in magnesium isoglycyrrhizinate group were lighter than those in control group. The number of CD8⁺ cells in the blood of magnesium isoglycyrrhizinate group was significantly less than that in the control group(P< 0. 05)and the CD4⁺/CD8⁺ cell ratio was significantly higher than that in the control group(P< 0. 05). The content of inflammatory cytokines in serum of magnesium isoglycyrrhizinate group decreased significantly(P< 0. 05). Magnesium isoglycyrrhizinate can regulate the immune function of HBV transgenic mouse, decrease the infiltration of inflammatory cells in hepatic tissue and hepatocyte injury, but do not affect the expression of hepatocyte HBsAg.
- magnesium isoglycyrrhizinate,
- hepatitis B,
- transgenic mouse,
- immunoregulation

FullText(HTML)

References (14)

References

[1]	Xie C,Li X,Zhu J,et al.Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264.7 cells[J].Bioorg Med Chem,2019,27(3):516-524.
[2]	Ma D,Zhang J,Zhang Y,et al.Inhibition of myocardial hypertrophy by magnesium isoglycyrrhizinate through the TLR4/NF-κB signaling pathway in mice[J].Int Immunopharmacol,2018,55:237-244.
[3]	Ou MH.Pharmacology and clinical research progress of magnesium isoglycyrrhizinate[J].China Pharm(中国药业),2010,19(15):83-85.
[4]	Guo WN,Zhu B,Ai L,et al.Animal models for the study of hepatitis B virus infection[J].Zool Res,2018,39(1):25-31.
[5]	Dupinay T,Gheit T,Roques P,et al.Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island[J].Hepatol,2013,58(5):1610-1620.
[6]	Dandri M,Volz TK,Lütgehetmann M,et al.Animal models for the study of HBV replication and its variants[J].J Clin Virol,2005,34(Suppl 1):S54-S62.
[7]	Chisari FV,Pinkert CA,Milich DR,et al.A transgenic mouse model of the chronic hepatitis B surface antigen carrier state[J].Science,1985,230(4730):1157-1160.
[8]	Babinet C,Farza H,Morello D,et al.Specific expression of hepatitis B surface antigen(HBsAg)in transgenic mouse[J].Science,1985,230(4730):1160-1163.
[9]	Guidotti L G,Matzke B,Schaller H,et al.High-level hepatitis B virus replication in transgenic mouse[J].J Virol,1995,69(10):6158-6169.
[10]	Kang AJ,Dong YH,Tian F,et al.Pathologic observation on C₅₇BL/6J-HBV transgenic mouse[J].Chin J Lab Anim Sci(中国实验动物学杂志),2002,12(1):8-10.
[11]	Huang LR,Wu HL,Chen PJ,et al.An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection[J].Proc Natl Acad Sci,2006,103(47):17862-17867.
[12]	Huang YH,Fang CC,Tsuneyama K,et al.A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery[J].Int J Oncol,2011,39(6):1511-1519.
[13]	Dembek C,Protzer U.Mouse models for therapeutic vaccination against hepatitis B virus[J].Med Microbiol Immunol,2015,204(1):95-102.
[14]	Zheng DM,Guo YH,Zheng F.Flow cytometry analysis of intrahepatic lymphocyte subsets in chronic hepatitis B[J].J Mod Med Health(现代医药卫生),2012,28(1):102-104.

Cited By

Get Citation

PDF

XML

Article views (518) PDF downloads (772)

Turn off MathJax

Article Contents

Abstract

References

Pharmacodynamic study of magnesium isoglycyrrhizinate in HBV transgenic mouse model

Abstract

References

Catalog

Export File

Citation

Format

Content